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Summary Microsatellite instability is a form of genetic damage that may be due to defective mismatch repair genes and may be a marker of
processes leading to malignancy. We have analysed a series of epithelial hyperplasia of usual type, carcinomas in situ and invasive and
metastatic carcinomas from the mammary gland on the assumption that they represent stages in the evolution of mammary carcinoma. Eight
markers on chromosomes 3p, 4q, 9p, 11p, 14q, 17p, 17q and Xq were examined for microsatellite instability and loss of heterozygosity. High
rates of loss on chromosomes 17p, 17q and Xq indicate that these chromosomal arms contain genes important in mammary carcinogenesis.
The rate of microsatellite instability observed in this study was uniformly low, irrespective of the lesion. This implies that microsatellite
instability is not a marker of malignancy in most instances of mammary neoplasia.
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Recent studies have focused on the impact of defective mismatch
repair (MMR) genes in the pathogenesis of malignancy, particu-
larly in hereditary non-polyposis colorectal carcinoma (Leach et
al, 1993; Bronner et al, 1994; Liu et al, 1994; Nicolaides et al,
1994; Papadopoulos et al, 1994; Han et al, 1995). The theory
suggests that cells with defective MMR mechanisms cannot
correct genetic errors that occur during cellular replication (Leach
et al, 1993; Parsons et al, 1993), e.g. point mutations, deletions,
insertions and strand slippage (Loeb, 1994). Thus, there is a reduc-
tion in the fidelity ofDNA replication. When errors occurin proto-
oncogenes and anti-oncogenes, loss of control over cell growth
and proliferation may develop. Thus, MMR defects have been
discussed recently as a mechanism of carcinogenesis equal in
importance to primary mutation of proto-oncogenes and anti-
oncogenes (Levine, 1995).
Microsatellites (also known as short tandem repeats or simple
sequence repeats) are sequences of DNA comprising multiple
copies of a repeat unit of 1-6 base pairs. They are common, poly-
morphic and distributed widely throughoutthe genome. Size insta-
bility in microsatellite DNA is associated with certain neurological
conditions (Willems, 1994) and has been demonstrated more
recently in a variety ofmalignant neoplasms (e.g. Han et al, 1993;
Peltomaki et al, 1993; Horii et al, 1994; Wooster et al, 1994).
There is in vitro evidence that cells with defective MMR genes
carry a high frequency oferrors in microsatellite sequences (Liu et
al, 1995). Tumours exhibiting microsatellite instability (MSI) are
said to have a replication error (RER+) phenotype (Aaltonen et al,
1993). In affected carcinomas, the number of repeat units in the
microsatellite increases or decreases, although the composition of
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the unit itself is unaffected (Mironov et al, 1994). This instability
is demonstrated by comparing DNA from the neoplasm to normal
DNA from the same patient. MSI may thus be a marker of defec-
tive MMR mechanisms.
The frequency of MSI in mammary carcinomas reported in the
literature has generally varied widely. Both Lothe et al (1993) and
Peltomaki et al (1993) saw no instances ofMSI in the same series
of 84 tumours using the same seven microsatellites. Han et al
(1993) recorded 1 of 26 (4%) cases exhibiting MSI with four
microsatellites; Wooster et al (1994) saw MSI in 11 of 104 (11%)
cases of mammary carcinoma when screening with a panel of 12
markers; Yee et al (1994) used seven microsatellites against 20
breast neoplasms and found instability in 4 of 20 (20%); and
Huang et al (1995) demonstrated instability in 9 of 29 (31%)
tumours with a series of 10 microsatellite markers. At extreme
odds with the other reports, Patel et al (1994) detected instability
in 11 of 13 (85%) tumours using nine microsatellites. In the total
of these series, MSI has been observed in only 36 of 276 (13%)
mammary neoplasms. The actual number of instances of insta-
bility was only 64 out of2499 (2.5%) but ranged from 0% (Lothe
et al, 1993; Peltomaki et al, 1993) to 34% (Patel et al, 1994). The
number ofinstances of MSI reported was below 1% in four ofthe
seven studies mentioned above and less than or equal to 6% for
six of the seven studies. The greatest problem when comparing
the different series is the fact that each group generally uses a
different set of microsatellite markers, thus making true compar-
ison impossible.
While MSI has been studied in a variety ofmalignant neoplasms,
its timing in carcinogenesis has notbeen systematically investigated.
Assuming that itplays a role in some instances, the timing ofMSI in
carcinogenesis may pinpoint its role either in the initiation of
carcinogenesis or in events that determine subsequent progression.
We consequently investigated the occurrence of MSI in epithelial
hyperplasia of usual type and in situ, invasive and metastatic carci-
nomas of the mammary gland on the assumption that the lesions
represent stages in the evolution ofmalignant neoplasia.
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Table 1 Microsatellite loci examined
Locus Associated gene Chromosomal location Repeattype Het Size range (bp)
D3S1514 - 3p21-14.2 n.a.a 0.83 200-280
FABP Fatty acid binding protein 4q31 MT 0.69 199-220
D9S254 MTSI 9p23-21 GATA 0.75 254-
TH01 Tyrosine hydroxylase 11p15.5 AATG 0.79 183-207
SCA3 MJD 14q32.1 CAG n.a. -230
D17S559 p53 17p13 CA 0.70 110-135
D17S855 BRCA1 17q12-21 CA 0.82 143-155
HUMARA Androgen receptor Xcen-q13 AGC 0.90 261-312
aD3S1514 is a tetranucleotide repeat, but the repeat unit is not known.
43 43 43 18 37 38
N T N T N T N T N T N T
D17S855 D3S1514 D9S254 HUMARA THo1 D3S1514
Figure 1 Examples of MSI. The case number is indicated at the top and the
locus at the bottom. N, normal DNA; T, tumour DNA. The novel alleles are
indicated (<)
MATERIALS AND METHODS
DNA samples from both normal and lesional tissue from 73
different patients were obtained from the Queen Elizabeth II
Medical Centre tissue bank. Similar paired DNA samples from a
further 48 patients were obtained from paraffin-embedded tissue
blocks from the Royal Perth Hospital Department of Pathology.
Each of these included a source of normal tissue (normal
mammary epithelium or normal lymph nodes) and one or more of
epithelial hyperplasia (18 specimens), carcinoma in situ (33 speci-
mens), invasive (100 specimens) or metastatic carcinoma (13
specimens; 12 were lymph node metastases and one a muscle
metastasis). In total, 164 specimens from 120 patients were
analysed. All DNA was extracted from the paraffin-embedded
tissues by methods described elsewhere (Turbett et al, 1996).
Normal tissue and either two orthree lesional types from the same
patient were obtained in 26 cases. There were two cases in which
DNA was obtained from normal tissue as well as samples of
epithelial hyperplasia, carcinoma in situ, invasive carcinoma and
metastatic tumour from the same patient. Of the 18 epithelial
hyperplasia specimens, normal tissue and one or more other
lesional type was obtained in 11 instances.
The microsatellite loci analysed included three tetranucleotides,
three trinucleotides and two dinucleotides (Table 1). Some of the
microsatellites were specifically chosen to represent chromosomes
known to be associated with breast malignancy, while others were
used because those chromosomal areas were not known to be
involved. The amplification buffer was 67 mm Tris-HCl (pH 8.8),
16.6 mm ammonium sulphate, 0.45% Triton X-100, 0.2 mg ml-'
gelatin, 0.2 mm dNTPs, 0.1JIM ofeach primer, 1-4 mM magnesium
chloride, 1 ,uCi [a-32P]dCTP (Redivue; Amersham, NSW, Australia)
and 0.5 units of Taq DNA polymerase per 25-,ul reaction.
Amplifications wereperformed on an MJ Research PTC-100 thermal
cyclerfitted with ahotbonnet (Watertown, MA, USA). Typical ther-
mocycle conditions were 94°C for 1 min, 50-60'C for 1 min and
72°C for 1 min, for a total of35 cycles. The initial denaturation and
final extension steps were extended to 5 min.
The tri- and tetranucleotide markers were analysed by electro-
phoresis of the PCR products on 8-10% 20-cm polyacrylamide
gels at 8-12 mA constant current for 12-15 h. This was followed
by silver staining using the method of Bassam et al (1991). The
dinucleotide markers and all cases of MSI found in silver-stained
gels were analysed on 6% polyacrylamide, 7 M urea, 40-cm poly-
acrylamide gels and subsequent autoradiography.
Every case was tested at seven ofthe loci, but there was insuffi-
cient DNA to test all samples at the THOl locus. Results were
scored by visual examination of the autoradiograph. MSI was
considered to have occurred if either allele in the tumour sample
showed altered electrophoretic mobility or if novel alleles were
present in the tumour sample in comparison with the normal.
Allelic loss was scored by visual examination of the autoradio-
graphs, and loss of heterozygosity (LOH) in tumour specimens
was considered to have occurred if there was a significant alter-
ation in the relative allele intensities between the two alleles for
the tumour sample compared with those from the normal sample.
Cases in which the lesional DNA was different to the normal were
counted as either MSI or LOH but not both; when both LOH and
MSI was seen, the result was scored as MSI only (for example, see
sample 18 at the HUMARA locus in Figure 1).
RESULTS
Of the 1274 instances tested, 1115 (88%) produced a result
(homozygous, heterozygous, LOH or MSI). All instances
producing a result were informative for the occurrence of MSI.
Instances showing MSI and homozygosity were not informative
for LOH. Tables 2 and 3 show the results of testing at each locus
for each lesion type. In epithelial hyperplasia, only one instance of
MSI was observed outofa total of 112, giving an overall incidence
of 0.9%. In the carcinomas in situ, there was only one occurrence
of MSI, at the FABP locus, giving a total occurrence of 0.6%. In
the invasive carcinomas, MSI was observed at all eight loci exam-
ined. The highest rate was seen at the D3S1514 locus, with 4 of94
(4.3%) cases exhibiting MSI. There were two occurrences at each
of D9S254 and HUMARA and one occurrence at each of the
remaining five loci. The total rate of MSI in the invasive carci-
nomas was 13 out of733 (1.8%), which was the highest rate seen.
There were no instances ofMSI seen at any locus in the metastatic
breast carcinomas, although the number of cases analysed was
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small. Ofthe 120 patients examined, the occurrence ofMSI at one
or more loci in any lesion type was seen in only 13 patients, giving
an overall occurrence of MSI in breast cancer patients of 10.8%.
Overall, there were 15 occurrences ofMSI seen in the 13 patients,
with only one case (0.83% ofall cases) showing MSI at more than
one locus. This was a medullary carcinoma, which exhibited MSI
at three loci: D3S1514, D9S254 and D17S855 (Figure 1).
Both expansion (larger allele) and contraction (smaller allele)
instabilities were observed, although contractions were far more
common (14 of 18 novel alleles). The three expansion instabilities
seen were for D3S1514, SCA3 and HUMARA. Other examples of
cases showing MSI are presented in Figure 1. Tumour 18 shows a
simple contraction instability, while tumours 37 and 38 exhibit
complex instabilities. Tumour 37 shows two novel contracted
alleles. One of the novel alleles present in tumour 38 is an expan-
sion, while the other cannot be classified as either. Because it is
present in the tumour sample at a molecular size intermediate to the
two original alleles, there is no way to determine whether it repre-
sents an expansion of the lower normal allele or a contraction of
the upper normal allele. A summary of the types of instabilities
observed are provided in Table 4. Overall, the rate ofobserved insta-
bility decreased as the size of the repeat unit decreased. From the
results in Table 2, it may be seen that the overall rate of instability
was 8 out of407 (2.0%) forthe tetranucleotides, 5 out of404 (1.2%)
for the trinucleotides and 2 out of304(0.66%) for the dinucleotides.
Of the 120 patients from whom samples were taken, LOH of at
least one of the eight loci was observed in 65 (54.2%). Of the 164
specimens analysed, 75 (45.7%) showed a loss of at least one
locus. The number of losses that occurred were zero (89, 54.3%),
one (38, 23.2%), two (15, 9.1%), three (17, 10.4%), four (4, 2.4%)
or five (1, 0.6%). The rate of LOH increased from 8% (7 of 88)
overall in the epithelial hyperplasias to 21.3% (13 of 61) in the
metastases. The highest rate of loss overall was seen in the meta-
stases, in which five of seven (71.4%) cases showed loss at the
THOI locus. In the epithelial hyperplasias, no instances of LOH
were seen at THO1 or HUMARA, but the other loci showed LOH
in 6-17% ofcases. For the carcinomas in situ, no LOH was seen at
D3S1514, FABP, D9S254 or THOI, but the other loci showed
LOH in 10-26% ofcases. LOH was seen at all loci in the invasive
carcinoma in 9-38% of cases. It was most common at D17S559
(38%, near thep53 gene at 17pl3) and D17S855 (32%, intragenic
to BRCAJ at 17ql2-q21). No LOH was observed at FABP or
D9S254 in the metastatic carcinoma, but 11-71% ofcases showed
LOH at the other sites. Examples ofLOH areprovided inFigure 2.
The more complex banding pattern presented by dinucleotides
(D17S855 and D17S559) can be readily compared with the
banding pattern oftrinucleotides (HUMARA) and tetranucleotides
(D3S1514, D9S254 and THO1).
There were no instances in which MSI was seen to occur in
more than one type oflesion obtainedfrom the samepatient. Thus,
the progression of an unstable allele from carcinoma in situ to
invasive carcinoma and metastatic carcinoma could not be
followed. However, there were instances when loss of an allele
was observed in multiple specimens from the same patient. Two
examples are provided in Figure 3. Samples of epithelial hyper-
plasia, carcinoma in situ, invasive ductal carcinoma and a lymph
node metastasis were obtained frompatient 100. Loss ofthe larger
D17S855 allele can be seen in the DNA from the epithelial hyper-
plasia. The same allele was lost in all subsequent lesions, including
the metastasis. At the SCA3 locus, patient 104 exhibited loss ofthe
smaller allele in both the invasive and the metastatic tumour
samples.
Table 2 Number of cases (%) of MSI in informative examples
Locus Epithelial hyperplasia Carcinoma in situ Invasive carcinoma Metastatic carcinoma Total
D3S1514 0/16 0/22 4/94 (4.3) 0/10 4/142 (2.8)
FABP 0/17 1/22(45) 1/88(1.1) 0/11 2/138(1.4)
D9S254 0/16 0/25 2/95 (2.1) 0/12 2/148 (1.4)
THOL 1/7(14.3) 0/11 1/88 (1.1) 0/11 2/117 (1.7)
SCA3 0/16 0/29 1/93c(1.1) 0/11 1/149(0.7)
D17S559 0/18 0/30 1/99 (1.0) 0/13 1/160 (0.6)
D17S855 0/14 0/26 1/91 (1.1) 0/13 1/144 (0.7)
HUMARA 0/8 0/16 2/85 (2.4) 0/8 2/117 (1.7)
TOTAL 1/112 (0.9) 1/181 (0.6) 13/733(1.8) 0/89 15/1115(1.3)
Table 3 Number of cases (%) of LOH in informative examplesa
Locus Epithelial hyperplasia Carcinoma in situ Invasive carcinoma Metastatic carcinoma Total
D3S1514 1/15 (6.7) 0/21 9/77 (11.7) 3/10 (30) 13/123 (10.6)
FABP 1/13 (7.7) 0/13 5/51 (9.8) 0/5 6/82 (7.3)
D9S254 1/11 (9.1) 0/18 7/62 (11.3) 0/6 8/97 (8.2)
TH01 0/4 0/7 9/68 (13.2) 5/7(71.4) 14/86 (16.3)
SCA3 2/12 (16.7) 4/22 (18.2) 6/66 (9.1) 1/8 (12.5) 13/108 (12)
D17S559 1/16 (6.3) 6/25 (24) 29/76 (38.2) 1/9 (11.1) 37/126 (29.4)
D17S855 1/11 (9.1) 4/18 (22.2) 24/75 (32) 2/11(18.2) 30/115 (26.1)
HUMARA 0/6 1/10 (10) 16/67 (23.9) 1/5(20) 18/88 (20.5)
TOTAL 7/88(8) 16/135 (11.9) 105/542 (19) 13/61 (21) 141/826 (17.1)
aThe total number of cases analysed here (826) is smaller than for the analysis of MSI (Table 2), as homozygous cases are informative for MSI but not for LOH.
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Table 4 Summary of microsatellite instabilities observed
Case Tissue type Locus Expansion/ Size of change'
contraction
9 IDC D3S1514 C 1
12 IDC HUMARA E 1
18 IDC HUMARA C 1Oc
37 IDC TH01 C 1,2
38 IDC D3S1514 E/?b 6 (E)c
41 IDC FABP C 2
43 M D3S1514 C 5, 7c
43 M D9S254 C 1
43 M D17S855 C 6c
93 IDC D3S1514 E/C 6c (E), 2c (C), 6c (C)
95 IDC SCA3 E 10
101 CIS FABP C 5
105 IDC D9S254 C 6c
144 IDC D17S559 C 4
146 EH TH1 --
Table 5 Significant correlations by Fisher's exact test
Tissue Event 1 Event 2 P-value
CIS LOH at D17S559 LOH at D17S855 0.0179
IDC LOH atD3S1514 LOH at D17S559 0.0193
LOH at D17S559 LOH at D17S855 0.00446
EH, CIS, IDC, Met LOH at D3S1514 LOH at D17S559 0.0151
LOH at D17S559 LOH at D17S855 0.000038
LOH at D17S559 LOH at HUMARA 0.0206
EH, epithelial hyperplasia; CIS, carcinoma in situ; IDC, invasive ductal
carcinoma; Met, metastatic carcinoma.
101
N EH CIS IDC LNM
105
N IDC LNM
aThe size of change is listed as number of repeat units. bCould not be
classified as an expansion or contraction instability. See text for details.
cThe change in repeat size was counted from the allele that showed reduced
intensity (LOH) in the tumour sample and was therefore assumed to be the
mutated allele. IDC, invasive ductal carcinoma; M, medullary carcinoma; CIS,
carcinoma in situ; EH, epithelial hyperplasia; E, expansion; C, contraction.
38 44 3 40 67 38
N T N T N T N T N T N T
Dl7S855 SCA3
< Figure 3 Examples of LOH in multiple lesions from the same patient. The
case number and lesional type of each tissue are provided at the top of each
lane. N, normal; EH, epithelial hyperplasia; CIS, carcinoma in situ; IDC,
invasive ductal carcinoma; LNM, lymph node metastasis. The locus analysed
is provided at the bottom. The lost alleles are indicated (<)
D17S855 D3S1514 D9S254 HUMARA THOI D17S559
Figure 2 Examples of LOH. The case number is indicated at the top and the
locus at the bottom. N, normal DNA; T, tumour DNA. The lost alleles are
indicated (<)
DISCUSSION
The overall cellular background rate of MSI in human tissues has
been estimated at 10- to 10-4 per locus per cell division (Heame et
al, 1992; Kwiatkowski et al, 1992), but the rate for mammary
tissues is not known. It is therefore difficult to determine the true
importance of MSI in mammary neoplasms (Dams et al, 1995),
although some conclusions can be drawn. The evidence obtained
here suggests thatMSI may develop at an early stage in the carcino-
genic process. MSI was first observed at low levels in epithelial
hyperplasia of usual type, indicating that a proportion of hyper-
plastic cells have already begun to accumulate genetic lesions. The
rate of MSI was similarly low in carcinoma in situ and invasive
carcinomas, while failure to detect MSI in metastases may be a
chance finding. There were no examples in which MSI was seen in
more than one type of lesion from the same patient. The very low
overall rates of MSI seen in epithelial hyperplasias, carcinomas in
situ and invasive carcinomas in this study suggest that MSI is
generally not a significant feature of these pathological states, and
is therefore not an important cause or effect of the processes
leading to their development. Moreover, MSI is not an indicator of
a mechanism necessary for the development ofmetastases.
Analysis of instability in chromosome 19 microsatellites by
Weber and Wong (1993) showed a clear preference for expansions
ratherthan contractions, with 77.5% ofinstabilities presenting as a
larger allele. In contrast, most instabilities observed in this study
were contractions, with only 3 of 13 (23%) expansion instabilities
seen. The reason forthis discrepancy is unknown. The observation
that the rate of instability was three times greater in the tetra-
nucleotides (2.0%) than in the dinucleotides (0.66%) has been
reported previously (Weber and Wong, 1993; Mao et al, 1994). It
would be worthwhile to investigate mononucleotide and penta-
nucleotide repeats to see whether this pattern continued. The
reason for this variation in the rate ofMSI between repeat types is
unknown; although Weber and Wong (1993) have suggested that
the discrepancy may be artefactual because ofthe under-reporting
of instances of MSI in dinucleotides due to the masking of novel
alleles by the strand slippage products common to dinucleotide
repeats. If this was the case, then one would not expect to see a
difference in the rate of instability between trinucleotides and
tetranucleotides, assuming a common mechanism for the develop-
ment ofinstability.
The fact that tetranucleotides appear to exhibit a greater rate of
instability than dinucleotides means that the results obtained in
any investigation screening forMSI will be highly dependent upon
the type of repeats chosen. A study using tetranucleotides would
be expected to find an incidence of MSI three times greater than
another study using dinucleotides. Furthermore, there is now
evidence that in particular tumour types, different microsatellite
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loci are inherently more likely to show instability than other loci
with the same repeat length. Mao et al (1996) have described a
method for detection of primary bladder cancers by microsatellite
analysis. They screened a series of 60 tri- and tetranucleotide
markers against 50 primary bladder cancers. They were able to
rank the markers according to their susceptibility to alteration and
select a panel of the 10 best microsatellite loci to use when
screening for bladder cancers. Their results would suggest that, at
least in bladder cancer, the rate of instability varies between
microsatellites. It would be useful to determine whether the
increased rates of instability seen in certain microsatellite loci are
specific to a particular tumour type (tumour-specific instability) or
whether these loci are generally prone to instability, regardless of
the type oftumour (general tumour instability).
A problem with defining the percentage of tumours in a given
study that show the RER+ phenotype is that an accurate definition
of what constitutes RER+ does not appear to be documented. It
would be of great value if all researchers could agree upon a
specific panel of microsatellite markers for the screening of
tumours for the presence of MSI. This would make comparisons
between research groups, different tumours and different tumour
types possible. Until such uniformity is achieved, direct compar-
isons of the results obtained by different research groups is impos-
sible and can lead to wildly different estimates ofthe rate ofMSI in
a given tumour type (Lothe et al, 1993; Peltomaki et al, 1993; Patel
et al, 1994). Ifthe presence of any MSI is assumed to be indicative
of an RER+ phenotype, then the rate of RER+ tumours seen in this
study was 10.8%, similar to that reported by Wooster et al (1994).
There are no universal sites of genetic damage known to occur
in mammary carcinoma. The background (random) rate ofLOH in
the mammary gland has been reported as 4% (Chen et al, 1992),
and previous reports suggest a frequency ofLOH at certain sites in
invasive carcinoma of 19-60% (Callahan and Campbell, 1989;
Ben Cheickh et al, 1992; Mooi and Peterse, 1992; Takita et al,
1992). While the D3S1514 (3p2l-pl4.2; Buchhagen et al, 1994),
D9S254 (9p23-p2l; Brenner and Aldaz, 1995) and THOI
(lpIS.5; Winqvist et al, 1993; Gudmundsson et al, 1995) loci
have been reported to be important in breast carcinogenesis, the
FABP and SCA3 loci were chosen as being representative ofchro-
mosomal regions thought to be irrelevant to mammary carcinogen-
esis. In the invasive carcinomas studied here, a similarly low rate
ofLOH (9.1-13%) was observed at the D3S1514, FABP, D9S254,
THOI and SCA3 loci, which is two to three times the background
rate reported by Chen et al (1992). The reason for this is unknown.
The remaining three loci showed high rates of LOH (24-38%),
suggesting that genes on chromosomes 17p, 17q and Xq may be
important in the development of invasive mammary carcinoma.
It has been previously reported that invasive carcinomas
showing LOH at lp are more likely to metastasize (Takita et al,
1992). Our study showed that LOH at this site occurred concur-
rently with the development of invasive carcinoma, and an even
higher rate of LOH was observed in metastases (Table 3). This
suggests that LOH at this site may be associated with the acquisi-
tion of an invasive phenotype and the ability to metastasize. On
chromosome 9p, LOH has previously been reported in 58% of
invasive carcinomas (Brenner and Aldaz, 1995), but this study
found LOH in only 11% ofinstances, and no instances ofloss were
seen in the metastatic tumours. LOH on both arms ofchromosome
17 and on Xq occurred concurrently with histological features of
carcinoma in situ and were present at a greater rate in invasive
carcinoma. The rate of loss for all three loci was actually seen to
decrease in the metastatic tumours, particularly the two chromo-
some 17 loci. LOH events at these sites may therefore have a role
in the expression of morphological or invasive characteristics but
not necessarily in the development of metastases.
There were significant associations between LOH ofmarkers on
both arms of chromosome 17 in all tissue grades (Table 5), which
suggests that allelic loss at these sites may be separate but associ-
ated events. It is also possible that the entire chromosome 17 is
deleted - study of additional chromosome 17 markers would
confirm the loss of the entire chromosome. We studied the
D17S855 microsatellite located within the BRCAJ gene, whose
mutation is associated with the development of familial mammary
carcinoma occurring at an early age (Chan, 1995). Loss of
heterozygosity at D17S855 suggests deletion of all or part of the
gene. To date, the timings of BRCAJ mutations and losses of
heterozygosity in mammary carcinogenesis have not been studied.
We observed one instance of loss at D17S855 in eleven epithelial
hyperplasias, 22% loss in carcinoma in situ and a 32% rate of loss
in invasive carcinomas; in metastatic carcinomas, the rate of loss
decreased to 18%. Our data imply that LOH of BRCAJ may be an
event that occurs early in mammary carcinogenesis (around the
stage of carcinoma in situ) and may also be observed in some
epithelial hyperplasias. In patient 80, samples of epithelial hyper-
plasia, carcinoma in situ and invasive ductal carcinoma were
analysed. Loss at the D17S855 locus was observed in the carci-
noma in situ and the invasive tumour DNA but not in the epithelial
hyperplasia. A high rate of LOH on 17q in invasive carcinoma and
the fact that only 1-2% of mammary carcinomas carry detectable
mutation in the BRCAJ gene (Chan, 1995) implies the presence of
other genes in the region that may have a role in mammary
carcinogenesis. Cropp et al (1993) have identified three discrete
regions of chromosome 17q that are frequently deleted in
mammary carcinomas.
Despite a high frequency ofLOH of D17S559 on 17p, there was
no correlation with mutation in exons 5-9 of thep53 gene (unpub-
lished data) located on this arm (P = 0.0683 using Fisher's exact
test), a finding supported by that of Deng et al (1994). Other
workers have noted that, in 60% of breast carcinomas showing
LOH at the p53 site, the retained allele is native, i.e. not mutated
(Moll et al, 1992). This implies that there may be other target sites
on this chromosome arm (Sato et al, 1991).
LOH at 3p showed a statistically significant association with
mutations in exons 5-9 of p53 (P = 0.0148 using Fisher's exact
test), which is located on chromosome 17p. This has been previ-
ously reported by Deng et al (1994). There were also significant
associations between LOH on chromosomes 3p and 17p (P =
0.0193 for invasive carcinoma alone; P = 0.0151 for hyperplasia,
carcinoma in situ, invasive and metastatic carcinoma). A major
role ofp53 is to act as a checkpoint factor by halting cell replica-
tion unless the genome is intact. Therefore, loss of normal p53
activity might allow persistence of errors in genes located on 3p. It
is also possible that mutations in p53 occur after LOH on 3p,
particularly as chromosome 3p carries the DNA mismatch repair
gene hMLHJ. LOH at this site might result in a down-grading of
the cell's ability to repair errors ofreplication.
When the rates ofLOH seen in all cases with MSI was compared
with the rates of LOH in all cases without MSI, there were no
apparent differences. Of the 13 cases that showed MSI, seven
(53.8%) showed no loss, while 82 of 151 (54.3%) cases without
MSI also showed no evidence of LOH. In the remaining six cases
with MSI, there were 13 occurrences of LOH. The number of
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occurrences of loss at each locus was as follows: D3S1514 (two),
FABP (one), D9S254 (zero), THOI (one), SCA3 (two), D17S559
(three), D17S855 (three) and HUMARA (one). The only case that
showed LOH at five of the eight loci tested also showed MSI,
while the single case that showed more than one instance of MSI
showed no LOH. Thus, there was no obvious association between
the occurrence of LOH and MSI within samples.
Overall, the occurrence ofany microsatellite alteration was 33%
in the epithelial hyperplasias and 32% in the carcinomas in situ,
but this almost doubled to 65% in the invasive tumours. Aldaz et al
(1995) reported that 74% of23 ductal carcinomas in situ showed at
least one alteration in a panel of 20 microsatellite markers. The
reason for the discrepancy between their results and those obtained
here may be attributed to the larger number of microsatellite
markers they used, as well as the locations of those markers. The
number ofmetastatic tumours analysed in this study that showed at
least one alteration was 46%, lower than for the invasive tumours.
The reason for this is unknown. The rates of LOH reported by
Aldaz et al (1995) for the ductal carcinomas in situ are in close
agreement with the results obtained in this study. They reported no
losses at 3p or lIp and high rates (25-30%) ofloss at 17p and 17q.
We saw no LOH at 3p or lIp and a rate ofLOH of24% at 17p and
22% at 17q.
The findings ofthis investigation suggest that, unlike hereditary
non-polyposis colorectal carcinoma, the RER+ phenotype is
uncommon, and MSI does not play a significant role in the initia-
tion or progression ofmost instances ofmammary carcinomas. We
did not observe a significant occurrence of MSI in the tumours
examined. MSI was seen in epithelial hyperplasias, carcinomas in
situ and invasive carcinomas, but the rate of instability observed
did not alter. This would indicate that the MSI seen in most
mammary neoplasms is some form of epiphenomenon that is of
neutral effect, not providing the tumour with either a selective
growth advantage or disadvantage. In contrast, LOH was a more
common phenomenon than MSI in all tissues studied, indicating
that it may be an important mechanism in the pathogenesis of
breast cancer.
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